{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:02:24Z","timestamp":1771023744872,"version":"3.50.1"},"reference-count":88,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The management of adrenal insufficiency (AI) is challenging, and the overall goals of treatment are to prevent life-threatening adrenal crises, to optimize linear growth, to control androgen levels without overdosing in patients with congenital adrenal hyperplasia (CAH), and to improve quality of life in affected individuals. Standard glucocorticoid formulations fail to replicate the circadian rhythm of cortisol and control the adrenal androgen production driven by adrenocorticotropin. To personalize and tailor glucocorticoid therapy and to improve patient outcomes, new pharmacological strategies have been developed that best mimic physiological cortisol secretion. Novel therapeutic approaches in the management of AI include new ways to deliver circadian cortisol replacement as well as various adjunctive therapies to reduce androgen production and\/or androgen action\/effects. Preclinical studies are exploring the role of restorative cell-based therapies, and a first recombinant adeno-associated virus-based gene therapy is also being developed in humans with CAH. In this article, we present 3 illustrative cases of AI with different underlying etiologies and times of presentation. Diagnostic and management processes are discussed with an emphasis on treatment and outcomes. We have also provided the most up-to-date evidence for the tailored management of children and adolescents with AI.<\/jats:p>","DOI":"10.1210\/clinem\/dgae564","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:21:22Z","timestamp":1724026882000},"page":"863-872","source":"Crossref","is-referenced-by-count":2,"title":["Approach to the Child and Adolescent With Adrenal Insufficiency"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6217-1919","authenticated-orcid":false,"given":"Giuseppa","family":"Patti","sequence":"first","affiliation":[{"name":"Department of Pediatrics, IRCCS Istituto Giannina Gaslini , Genoa 16100 ,","place":["Italy"]},{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova , Genoa 16100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Zucconi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, IRCCS Istituto Giannina Gaslini , Genoa 16100 ,","place":["Italy"]},{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova , Genoa 16100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Matarese","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, IRCCS Istituto Giannina Gaslini , Genoa 16100 ,","place":["Italy"]},{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova , Genoa 16100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Tedesco","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, IRCCS Istituto Giannina Gaslini , Genoa 16100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Panciroli","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, IRCCS Istituto Giannina Gaslini , Genoa 16100 ,","place":["Italy"]},{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova , Genoa 16100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-6118","authenticated-orcid":false,"given":"Flavia","family":"Napoli","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, IRCCS Istituto Giannina Gaslini , Genoa 16100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-4585","authenticated-orcid":false,"given":"Natascia","family":"Di Iorgi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, IRCCS Istituto Giannina Gaslini , Genoa 16100 ,","place":["Italy"]},{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova , Genoa 16100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-5238","authenticated-orcid":false,"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, IRCCS Istituto Giannina Gaslini , Genoa 16100 ,","place":["Italy"]},{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova , Genoa 16100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"issue":"3","key":"2025021815501657600_dgae564-B1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/adc.51.3.170","article-title":"Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty","volume":"51","author":"Tanner","year":"1976","journal-title":"Arch Dis Child"},{"key":"2025021815501657600_dgae564-B2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1651-2227.2006.tb02378.x","article-title":"WHO child growth standards based on length\/height, weight and age","volume":"450","author":"WHO Multicentre Growth Reference Study Group","year":"2006","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"2025021815501657600_dgae564-B3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.beem.2018.03.012","article-title":"Central adrenal insufficiency in children and adolescents","volume":"32","author":"Patti","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2025021815501657600_dgae564-B4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/cen.13001","article-title":"Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency","volume":"84","author":"King","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025021815501657600_dgae564-B5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"issue":"6","key":"2025021815501657600_dgae564-B6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ando.2017.10.007","article-title":"Group 4: replacement therapy for adrenal insufficiency","volume":"78","author":"Castinetti","year":"2017","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"2025021815501657600_dgae564-B7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2025021815501657600_dgae564-B8","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1210\/jc.2009-2616","article-title":"Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis","volume":"95","author":"Muthusamy","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025021815501657600_dgae564-B9","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815501657600_dgae564-B10","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-21-0794","article-title":"Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia","volume":"186","author":"Prete","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025021815501657600_dgae564-B11","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1542\/peds.2006-1612","article-title":"Adrenal insufficiency: still a cause of morbidity and death in childhood","volume":"119","author":"Shulman","year":"2007","journal-title":"Pediatrics"},{"issue":"4","key":"2025021815501657600_dgae564-B12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1210\/jc.2014-4060","article-title":"Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency","volume":"100","author":"Whitaker","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815501657600_dgae564-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-013-0005-9","article-title":"Potential risks of pharmacy compounding","volume":"13","author":"Gudeman","year":"2013","journal-title":"Drugs R D"},{"issue":"6","key":"2025021815501657600_dgae564-B14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40272-018-0306-0","article-title":"The challenges of cortisol replacement therapy in childhood: observations from a case series of children treated with modified-release hydrocortisone","volume":"20","author":"Park","year":"2018","journal-title":"Paediatr Drugs"},{"issue":"2","key":"2025021815501657600_dgae564-B15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12020-022-03007-w","article-title":"Mini-review: pump therapy in endocrinology & metabolism beyond diabetes","volume":"76","author":"Helvac\u0131","year":"2022","journal-title":"Endocrine"},{"key":"2025021815501657600_dgae564-B16","doi-asserted-by":"crossref","first-page":"751191","DOI":"10.3389\/fendo.2021.751191","article-title":"24-hour profiles of 11-oxygenated c19 steroids and \u03b45-steroid sulfates during oral and continuous subcutaneous glucocorticoids in 21-hydroxylase deficiency","volume":"12","author":"Turcu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2025021815501657600_dgae564-B17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cen.13813","article-title":"Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia","volume":"89","author":"Mallappa","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025021815501657600_dgae564-B18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrendo.2011.161","article-title":"Aromatase inhibitors in pediatrics","volume":"8","author":"Wit","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2025021815501657600_dgae564-B19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1210\/jcem.85.3.6462","article-title":"Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia","volume":"85","author":"Merke","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025021815501657600_dgae564-B20","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1210\/jc.2014-1258","article-title":"Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency","volume":"99","author":"Auchus","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025021815501657600_dgae564-B21","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2015-3574","article-title":"Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency","volume":"101","author":"Turcu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025021815501657600_dgae564-B22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-17-0248","article-title":"Quality of compounded hydrocortisone capsules used in the treatment of children","volume":"177","author":"Neumann","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025021815501657600_dgae564-B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen.13447","article-title":"Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency","volume":"88","author":"Neumann","year":"2018","journal-title":"ClinEndocrinol (Oxf)"},{"issue":"3","key":"2025021815501657600_dgae564-B24","doi-asserted-by":"crossref","first-page":"e1433","DOI":"10.1210\/clinem\/dgaa626","article-title":"A prospective study of children aged 0-8 years with CAH and adrenal insufficiency treated with hydrocortisone granules","volume":"106","author":"Neumann","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815501657600_dgae564-B25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/EJE-09-0170","article-title":"Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study","volume":"161","author":"Johannsson","year":"2009","journal-title":"Eur J Endocrinold"},{"issue":"2","key":"2025021815501657600_dgae564-B26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","author":"Johannsson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815501657600_dgae564-B27","author":"US National Library of Medicine"},{"issue":"3","key":"2025021815501657600_dgae564-B28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40618-022-01940-1","article-title":"Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency","volume":"46","author":"Gasco","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2025021815501657600_dgae564-B29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/cen.12316","article-title":"An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure","volume":"80","author":"Whitaker","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025021815501657600_dgae564-B30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2265.2009.03636.x","article-title":"A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia","volume":"72","author":"Verma","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025021815501657600_dgae564-B31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2014-3809","article-title":"A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia","volume":"100","author":"Mallappa","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025021815501657600_dgae564-B32","first-page":"1797","article-title":"Modified-release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia","volume":"102","author":"Jones","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025021815501657600_dgae564-B33","doi-asserted-by":"crossref","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","article-title":"Modified-release hydrocortisone in congenital adrenal hyperplasia","volume":"106","author":"Merke","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815501657600_dgae564-B34","doi-asserted-by":"crossref","first-page":"lvac006","DOI":"10.1093\/ejendo\/lvac006","article-title":"Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia","volume":"188","author":"Tschaidse","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025021815501657600_dgae564-B35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/cen.12453","article-title":"The child with difficult to control Congenital Adrenal Hyperplasia: is there a place for continuous subcutaneous hydrocortisone therapy","volume":"81","author":"Hindmarsh","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7-8","key":"2025021815501657600_dgae564-B36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1515\/jpem.2011.226","article-title":"Continuous subcutaneous hydrocortisone infusion (CSHI) in a young adolescent with congenital adrenal hyperplasia (CAH)","volume":"24","author":"Tuli","year":"2011","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9","key":"2025021815501657600_dgae564-B37","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1210\/jc.2009-0630","article-title":"Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion","volume":"94","author":"Bryan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815501657600_dgae564-B38","first-page":"150005","article-title":"Management of adrenocortical insufficiency with continuous subcutaneous hydrocortisone infusion: long-term experience in three patients","volume":"2015","author":"Khanna","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"2025021815501657600_dgae564-B39","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12020-018-1780-4","article-title":"Continuous subcutaneous hydrocortisone infusion in a woman with secondary adrenal insufficiency","volume":"63","author":"Cardini","year":"2019","journal-title":"Endocrine"},{"issue":"3","key":"2025021815501657600_dgae564-B40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11154-022-09717-w","article-title":"Novel treatments for congenital adrenal hyperplasia","volume":"23","author":"Schr\u00f6der","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"2025021815501657600_dgae564-B41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4158\/EP-2019-0610","article-title":"Aromatase inhibitor increases the height of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"26","author":"Xi","year":"2020","journal-title":"Endocr Pract"},{"key":"2025021815501657600_dgae564-B42","author":"US National Library of Medicine"},{"key":"2025021815501657600_dgae564-B43","author":"US National Library of Medicine"},{"issue":"8","key":"2025021815501657600_dgae564-B44","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1210\/clinem\/dgaa381","article-title":"A phase 2, multicenter study of nevanimibe for the treatment of congenital adrenal hyperplasia","volume":"105","author":"El-Maouche","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025021815501657600_dgae564-B45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0306-4530(95)00011-9","article-title":"Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders","volume":"20","author":"De Souza","year":"1995","journal-title":"Psychoneuroendocrinology"},{"issue":"11","key":"2025021815501657600_dgae564-B46","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1210\/clinem\/dgad270","article-title":"Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia","volume":"108","author":"Newfield","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025021815501657600_dgae564-B47","first-page":"1","article-title":"ALD1613, a novel long-acting monoclonal antibody to control acth-driven pharmacology","volume":"158","author":"Feldhaus","year":"2017","journal-title":"Endocrinology"},{"issue":"7","key":"2025021815501657600_dgae564-B48","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/en.2019-00117","article-title":"A long-acting neutralizing monoclonal acth antibody blocks corticosterone and adrenal gene responses in neonatal rats","volume":"160","author":"Gehrand","year":"2019","journal-title":"Endocrinology"},{"key":"2025021815501657600_dgae564-B49","author":"Crinetics","year":"2021"},{"issue":"4","key":"2025021815501657600_dgae564-B50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11259-018-9737-x","article-title":"Melanocortin 2 receptor antagonists in canine pituitary-dependent hypercortisolism: in vitro studies","volume":"42","author":"Sanders","year":"2018","journal-title":"Vet Res Commun"},{"issue":"1","key":"2025021815501657600_dgae564-B51","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1152\/ajpregu.00009.2018","article-title":"Effect of a melanocortin type 2 receptor (MC2R) antagonist on the corticosterone response to hypoxia and ACTH stimulation in the neonatal rat","volume":"315","author":"Goldenberg","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5","key":"2025021815501657600_dgae564-B52","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1210\/jc.2018-00217","article-title":"Bilateral adrenalectomy in congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"103","author":"MacKay","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025021815501657600_dgae564-B53","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1210\/jc.2002-022026","article-title":"The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia","volume":"88","author":"Van Wyk","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025021815501657600_dgae564-B54","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2025021815501657600_dgae564-B55","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"issue":"2","key":"2025021815501657600_dgae564-B56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ecl.2018.01.006","article-title":"Medical therapy for Cushing's syndrome in the twenty-first century","volume":"47","author":"Tritos","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"21","key":"2025021815501657600_dgae564-B57","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMc1410041","article-title":"Mitotane for 21-hydroxylase deficiency in an infertile man","volume":"371","author":"Bry-Gauillard","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2025021815501657600_dgae564-B58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/EJE-20-0787","article-title":"Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective series of five patients","volume":"184","author":"Bachelot","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2025021815501657600_dgae564-B59","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1210\/clinem\/dgac751","article-title":"Future directions for adrenal insufficiency: cellular transplantation and genetic therapies","volume":"108","author":"Graves","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025021815501657600_dgae564-B60","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/clinem\/dgaa438","article-title":"New horizons: novel adrenal regenerative therapies","volume":"105","author":"Bornstein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025021815501657600_dgae564-B61","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1073\/pnas.1500242112","article-title":"Transplantation of bovine adrenocortical cells encapsulated in alginate","volume":"112","author":"Balyura","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"51","key":"2025021815501657600_dgae564-B62","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1073\/pnas.1814072115","article-title":"Isolation and characterization of adrenocortical progenitors involved in the adaptation to stress","volume":"115","author":"Steenblock","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2025021815501657600_dgae564-B63","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/sj.gt.3301018","article-title":"Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochrome P450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice","volume":"6","author":"Tajima","year":"1999","journal-title":"Gene Ther"},{"issue":"10","key":"2025021815501657600_dgae564-B64","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1507\/endocrj.EJ16-0112","article-title":"Extra-adrenal induction of Cyp21a1 ameliorates systemic steroid metabolism in a mouse model of congenital adrenal hyperplasia","volume":"63","author":"Naiki","year":"2016","journal-title":"Endocr J"},{"issue":"4","key":"2025021815501657600_dgae564-B65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/hum.2017.203","article-title":"Biology of the adrenal gland cortex obviates effective use of adeno-associated virus vectors to treat hereditary adrenal disorders","volume":"29","author":"Markmann","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"5","key":"2025021815501657600_dgae564-B66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/gt.2017.10","article-title":"An AAVrh10-CAG-CYP21- HA vector allows persistent correction of 21-hydroxylase deficiency in a Cyp21(-\/-) mouse model","volume":"24","author":"Perdomini","year":"2017","journal-title":"Gene Ther"},{"issue":"15-16","key":"2025021815501657600_dgae564-B67","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1089\/hum.2022.005","article-title":"Adeno-associated virus-mediated gene therapy for patients\u2019 fibroblasts, induced pluripotent stem cells, and a mouse model of congenital adrenal hyperplasia","volume":"33","author":"Naiki","year":"2022","journal-title":"Hum Gene Ther"},{"key":"2025021815501657600_dgae564-B68","first-page":"4135","article-title":"OR25-01 durable CYP21A2 gene therapy in non-human primates for treatment of congenital adrenal hyperplasia","volume":"2020","author":"Eclov","year":"2020","journal-title":"J Endocr Soc"},{"key":"2025021815501657600_dgae564-B69","doi-asserted-by":"crossref","first-page":"A82","DOI":"10.1210\/jendso\/bvab048.165","article-title":"Design of a phase 1\/2 open-label, dose-escalation study of the safety and efficacy of gene therapy in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency through administration of an adeno-associated virus (AAV) serotype 5-based recombinant vector encoding the human CYP21A2 gene","volume":"5","author":"Merke","year":"2021","journal-title":"J Endocr Soc"},{"issue":"3","key":"2025021815501657600_dgae564-B70","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther"},{"key":"2025021815501657600_dgae564-B71","author":"US National Library of Medicine"},{"issue":"10274","key":"2025021815501657600_dgae564-B72","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","article-title":"Adrenalin sufficiency","volume":"397","author":"Husebye","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2025021815501657600_dgae564-B73","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ecl.2022.04.003","article-title":"Quality of life in patients with adrenal insufficiency","volume":"51","author":"Li","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"2025021815501657600_dgae564-B74","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1210\/jc.2007-0685","article-title":"Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis","volume":"92","author":"Hahner","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815501657600_dgae564-B75","doi-asserted-by":"crossref","first-page":"761258","DOI":"10.3389\/fendo.2021.761258","article-title":"Long-term health outcomes of Korean adults with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"12","author":"Lim","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025021815501657600_dgae564-B76","doi-asserted-by":"crossref","first-page":"1005963","DOI":"10.3389\/fendo.2022.1005963","article-title":"Treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: a modified Delphi consensus study","volume":"13","author":"Auchus","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025021815501657600_dgae564-B77","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/cen.13719","article-title":"Quality of life in patients with adrenal disease: a systematic review","volume":"89","author":"Ho","year":"2018","journal-title":"ClinEndocrinol (Oxf)"},{"issue":"2","key":"2025021815501657600_dgae564-B78","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000430863","article-title":"Adult quality of life and psychosocial outcomes of childhood onset hypopituitarism","volume":"84","author":"Kao","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2025021815501657600_dgae564-B79","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1210\/clinem\/dgad405","article-title":"Quality of life in children and young people with congenital adrenal hyperplasia\u2014UK nationwide multicentre assessment","volume":"109","author":"Lawrence","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815501657600_dgae564-B80","doi-asserted-by":"crossref","first-page":"1122435","DOI":"10.3389\/fendo.2023.1122435","article-title":"The clinical characteristics and quality of life of 248 pediatric and adult patients with Congenital Adrenal Hyperplasia","volume":"14","author":"Shafaay","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2025021815501657600_dgae564-B81","doi-asserted-by":"crossref","first-page":"e2851","DOI":"10.1210\/clinem\/dgac175","article-title":"Quality of life and its determinants in patients with adrenal insufficiency: a survey study at 3 centers in the United States","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025021815501657600_dgae564-B82","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMra1807486","article-title":"Adrenal crisis","volume":"381","author":"Rushworth","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2025021815501657600_dgae564-B83","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1210\/clinem\/dgaa694","article-title":"Real-world estimates of adrenal insufficiency-related adverse events in children with congenital adrenal hyperplasia","volume":"106","author":"Ali","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025021815501657600_dgae564-B84","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1210\/jc.2010-0917","article-title":"United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients","volume":"95","author":"Arlt","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"2025021815501657600_dgae564-B85","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"383","author":"Merke","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2025021815501657600_dgae564-B86","first-page":"e5247","article-title":"Cardiovascular disease risk factors and metabolic morbidity in a longitudinal study of congenital adrenal hyperplasia","volume":"106","author":"Torky","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815501657600_dgae564-B87","doi-asserted-by":"crossref","first-page":"1129584","DOI":"10.3389\/fendo.2023.1129584","article-title":"Depressive and anxiety disorders and antidepressant prescriptions among insured children and young adults with congenital adrenal hyperplasia in the United States","volume":"14","author":"Harasymiw","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025021815501657600_dgae564-B88","doi-asserted-by":"crossref","first-page":"600962","DOI":"10.3389\/fped.2020.600962","article-title":"Congenital hypopituitarism during the neonatal period: epidemiology, pathogenesis, therapeutic options, and outcome","volume":"8","author":"Bosch I Ara","year":"2021","journal-title":"Front Pediatr"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae564\/58922793\/dgae564.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/863\/58922793\/dgae564.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/863\/58922793\/dgae564.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:10:38Z","timestamp":1739895038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/3\/863\/7735410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,18]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae564","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,8,18]]}}}